BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 9605121)

  • 1. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
    Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
    J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
    J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K; Bonardelle D; Bobé P; Kiger N
    Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
    de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
    Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
    Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
    J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
    Williams NS; Engelhard VH
    J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine-insensitive partial signaling and multiple roles of Ca2+ in Fas ligand-induced lysis.
    Rogers AM; Thilenius AR; Russell JH
    J Immunol; 1997 Oct; 159(7):3140-7. PubMed ID: 9317111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL.
    Kojima H; Eshima K; Takayama H; Sitkovsky MV
    J Immunol; 1997 Sep; 159(6):2728-34. PubMed ID: 9300693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and Lyt-2, 3. II. Evidence that trypsin pretreatment of target cells removes a non-H-2 molecule important in killing.
    Gromkowski SH; Heagy W; Martz E
    J Immunol; 1985 Jan; 134(1):70-7. PubMed ID: 3880579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
    Lowin B; Hahne M; Mattmann C; Tschopp J
    Nature; 1994 Aug; 370(6491):650-2. PubMed ID: 7520535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anergic cytotoxic T lymphocyte clone exhibits granule exocytosis-mediated cytotoxicity.
    Kuwano K; Akashi A; Arai S
    Cell Immunol; 1998 May; 185(2):114-22. PubMed ID: 9636689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
    Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
    J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of requirement for SHP-1 in both Fas-mediated and perforin-mediated cell death induced by CTL.
    Takayama H; Lee MH; Shirota-Someya Y
    J Immunol; 1996 Nov; 157(9):3943-8. PubMed ID: 8892626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms.
    Smith DJ; McGuire MJ; Tocci MJ; Thiele DL
    J Immunol; 1997 Jan; 158(1):163-70. PubMed ID: 8977187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
    Li Q; Nakadai A; Takeda K; Kawada T
    Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CPP32-like proteases prevents granzyme B- and Fas-, but not granzyme A-based cytotoxicity exerted by CTL clones.
    Anel A; Gamen S; Alava MA; Schmitt-Verhulst AM; Piñeiro A; Naval J
    J Immunol; 1997 Mar; 158(5):1999-2006. PubMed ID: 9036942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
    Bachmann MF; Ohteki T; Faienza KM; Zakarian A; Kägi D; Speiser DE; Ohashi PS
    J Immunol; 1997 Nov; 159(9):4165-70. PubMed ID: 9379009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.